RNS Number : 1007F
  Hikma Pharmaceuticals Plc
  03 October 2008
   

    


    Hikma Pharmaceuticals PLC - Voting Rights and Capital

    LONDON, 3 October 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) notifies the market that as at 30 September 2008 its capital
consists of 188,822,807 ordinary shares with voting rights. There are no shares held in treasury.

    The above figure (188,822,807) may be used by shareholders as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and
Transparency Rules. 

    - ENDS -
    Enquiries:

 Hikma Pharmaceuticals PLC
 Henry Knowles              +44 20 7399 2760
 Company Secretary




    About Hikma
    Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both
branded and non-branded generic and in-licensed pharmaceutical products.  Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics".  Hikma's operations are based principally in the Middle East and North Africa ("MENA") region,
where it is a market leader and sells across 17 countries, the United States and Europe.  In 2007, the Group achieved revenues of $449
million (2006 $317 million) and profit attributable to shareholders was $63 million (2006 $55 million).  For news and other information,
please visit www.hikma.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
TVREASEDELXPFFE
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.